✦ LIBER ✦

Immunogenicity of low-dose plasma-derived hepatitis B vaccine

✍ Scribed by Mark Kane; Julie Milstien

Book ID: 118553229
Publisher: The Lancet
Year: 1997
Tongue: English
Weight: 147 KB
Volume: 350
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(05)70464-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immunogenicity of plasma-derived hepatit

Immunogenicity of plasma-derived hepatitis B vaccine

✍ Stanely M. Lemon; Davis J. Weber 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB

Immunogenicity of plasma-derived Hepatit

Immunogenicity of plasma-derived Hepatitis B vaccine in preterm infants

✍ K. Ravi Shankar; R. K. Dhiman; Anil Narang 📂 Article 📅 2000 🏛 Springer-Verlag 🌐 English ⚖ 336 KB

Comparative immunogenicity in children o

Comparative immunogenicity in children of mammalian cell-derived recombinant hepatitis B vaccine and plasma-derived hepatitis B vaccine

✍ P. Coursaget; L. Bringer; G. Sarr; C. Bourdil; B. Fritzell; C. Blondeau; B. Yvon 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 355 KB

Recombinant versus plasma-derived hepati

Recombinant versus plasma-derived hepatitis B vaccine: comparison of immunogenicity in medical students

✍ Johannes Möst; Clara Larcher; Werner Vogetseder; Wolfgang M. Prodinger; Hartwig 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 133 KB

Immunogenicity of low doses of recombina

Immunogenicity of low doses of recombinant hepatitis B vaccine in young males

✍ C. Tsakalakis; S.C. Richardson; A. Roumeliotou-Karayannis; G. Papaevangelou 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 277 KB

Immunogenicity of a five-microgram dose

Immunogenicity of a five-microgram dose of hepatitis B vaccine

✍ George Papaevangelou; Anastasia Roumeliotou-Karayannis; Charalambos Vissoulis; S 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 291 KB

The immunogenicity of a 5-micrograms dose of vaccine (H-B-Vax, MSD) was evaluated in 50 young adults (17-19 years). Results were compared to our previous studies using similarly prepared vaccines using 20 micrograms and 10 micrograms per dose with the same trial protocol in a comparable population.